Jasper Therapeutics, Inc., a clinical-stage biotechnology company, develops therapeutic agents for hematopoietic stem cell transplantation and gene therapies. The company develops JSP191, a humanized monoclonal antibody for clearing hematopoietic stem cells from bone marrow in patients undergoing a hematopoietic cell transplantation. It also develops Jasper eHSC Platform to overcome key limitations of allogeneic and autologous gene-edited stem cell grafts. The company is based in Redwood City, California.
IPO Year: 2020
Exchange: NASDAQ
Website: jaspertherapeutics.com
| Date | Price Target | Rating | Analyst |
|---|---|---|---|
| 2/13/2025 | $38.00 | Buy | UBS |
| 12/6/2024 | $63.00 | Outperform | BMO Capital Markets |
| 9/9/2024 | $70.00 | Mkt Outperform | JMP Securities |
| 7/8/2024 | $90.00 | Buy | BTIG Research |
| 6/27/2024 | $86.00 | Buy | Stifel |
| 5/6/2024 | $65.00 | Buy | H.C. Wainwright |
| 4/3/2024 | $65.00 | Outperform | Evercore ISI |
| 3/28/2024 | $70.00 | Outperform | RBC Capital Mkts |
| 3/18/2024 | Outperform | TD Cowen | |
| 8/11/2023 | $7.00 | Overweight | CapitalOne |